← Browse by Condition
Medical Condition

leptomeningeal metastasis

Total Trials
2
Recruiting Now
2
Trial Phases
Phase 1, Phase 2

ClinicalMetric tracks all active clinical trials for leptomeningeal metastasis sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — leptomeningeal metastasis Clinical Trials

How many clinical trials are currently recruiting for leptomeningeal metastasis?
ClinicalMetric currently tracks 2 actively recruiting clinical trials for leptomeningeal metastasis, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 2. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for leptomeningeal metastasis?
leptomeningeal metastasis research spans Phase 1 (1 trial), Phase 2 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a leptomeningeal metastasis clinical trial?
Eligibility criteria for leptomeningeal metastasis trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
1
Phase 2
1
Top Sponsors
Guangzhou Medical University 1 trial
Henan Cancer Hospital 1 trial

Recruiting Clinical Trials

NCT06809517 Phase 1, Phase 2
Recruiting
Intrathecal PD-1/VEGF Bispecific Antibody Plus Pemetrexed for Leptomeningeal Metastasis
Enrollment
34 pts
Location
China
Sponsor
Guangzhou Medical University
View Trial →
NCT06643000
Recruiting
Evaluating High-dose Furmonertinib with Bevacizumab and Pemetrexed for EGFRm NSCLC with Leptomeningeal Metastasis
Enrollment
60 pts
Location
China
Sponsor
Henan Cancer Hospital
View Trial →

Related Conditions

intrathecal drug delivery (1) non small cell lung cancer (1) egfr gene mutation (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology